February 24, 2022 Other Open Access

Meredith Smith; Serena Oliveri; Monica Casiraghi

DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.6260511</identifier>
  <creators>
    <creator>
      <creatorName>Meredith Smith</creatorName>
      <affiliation>Alexion</affiliation>
    </creator>
    <creator>
      <creatorName>Serena Oliveri</creatorName>
      <affiliation>European Institute of Oncology</affiliation>
    </creator>
    <creator>
      <creatorName>Monica Casiraghi</creatorName>
      <affiliation>European Institute of Oncology</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Treating non-small cell lung cancer: What do patients PREFER</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2022</publicationYear>
  <subjects>
    <subject>Plain language summary</subject>
    <subject>Case study</subject>
  </subjects>
  <contributors>
    <contributor contributorType="Researcher">
      <contributorName>Rosanne Janssens</contributorName>
      <affiliation>KU Leuven</affiliation>
    </contributor>
    <contributor contributorType="Researcher">
      <contributorName>Isabelle Huys</contributorName>
      <affiliation>KU Leuven</affiliation>
    </contributor>
    <contributor contributorType="Researcher">
      <contributorName>Ian Smith</contributorName>
      <affiliation>University Medical Centre Utrecht</affiliation>
    </contributor>
    <contributor contributorType="Researcher">
      <contributorName>Charis Girvalaki</contributorName>
      <affiliation>European Cancer Patient Coalition</affiliation>
    </contributor>
    <contributor contributorType="Researcher">
      <contributorName>Ardine de Wit</contributorName>
      <affiliation>University Medical Centre Utrecht</affiliation>
    </contributor>
    <contributor contributorType="Researcher">
      <contributorName>Jorien Veldwijk</contributorName>
      <affiliation>Erasmus University Rotterdam</affiliation>
    </contributor>
    <contributor contributorType="Researcher">
      <contributorName>Lucilla Lanzoni</contributorName>
      <affiliation>European Institute of Oncology</affiliation>
    </contributor>
  </contributors>
  <dates>
    <date dateType="Issued">2022-02-24</date>
  </dates>
  <resourceType resourceTypeGeneral="Other"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/6260511</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.6260510</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/prefer</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;We wanted to learn about lung cancer patients&amp;rsquo;&amp;nbsp;preferences for new treaments, and what they considered to be the maximum acceptable risk, and the minimum acceptable benefit of a treatment.&lt;/p&gt;</description>
  </descriptions>
  <fundingReferences>
    <fundingReference>
      <funderName>European Commission</funderName>
      <funderIdentifier funderIdentifierType="Crossref Funder ID">10.13039/100010661</funderIdentifier>
      <awardNumber awardURI="info:eu-repo/grantAgreement/EC/H2020/115966/">115966</awardNumber>
      <awardTitle>Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966</awardTitle>
    </fundingReference>
  </fundingReferences>
</resource>